高级检索
    周清. 帕博利珠单抗治疗初治PD-L1阳性局部晚期/转移性非小细胞肺癌:KEYNOTE-042中国拓展研究[J]. 循证医学, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003
    引用本文: 周清. 帕博利珠单抗治疗初治PD-L1阳性局部晚期/转移性非小细胞肺癌:KEYNOTE-042中国拓展研究[J]. 循证医学, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003
    shu
    ZHOU Qing. Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003
    Citation: ZHOU Qing. Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003
    shu

    帕博利珠单抗治疗初治PD-L1阳性局部晚期/转移性非小细胞肺癌:KEYNOTE-042中国拓展研究

    Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study

      摘要
      • HTML全文
      • 参考文献(6)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回